|Articles|March 19, 2020

Call To Pool Research Resources into Large Trials to Generate Evidence On COVID-19 Treatments

EMA’s Human Medicines Committee has published a statement urging the EU research community to prioritize large randomized controlled studies because they are most likely to generate the conclusive evidence needed to enable rapid development and approval of potential treatments of COVID-19. The statement promotes a harmonized approach to data collection for COVID-19 clinical trials across the EU.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.